Kidney disease news - the latest biotech news from Labiotech.eu

Virus tracking could be key to kidney transplant patients’ drug choices

External Contributor — Fri, 30 Jun 2023 08:32:49 +0000

By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […]

The post Virus tracking could be key to kidney transplant patients’ drug choices appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Novartis acquires Chinook Therapeutics for $3.2B

Jim Cornall — Fri, 16 Jun 2023 09:30:00 +0000

Novartis has entered into an agreement to acquire Chinook Therapeutics, a Seattle, Washington, based clinical stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed deal, which is subject to customary closing conditions, is in line with Novartis’ strategy to focus on innovative medicines and will expand […]

The post Novartis acquires Chinook Therapeutics for $3.2B appeared first on Labiotech.eu.

FDA fast track for Memo’s kidney transplant infection treatment

Jim Cornall — Tue, 02 May 2023 10:41:47 +0000

Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […]

The post FDA fast track for Memo’s kidney transplant infection treatment appeared first on Labiotech.eu.

New research may lead to gene therapies for kidney disease

Jim Cornall — Tue, 04 Apr 2023 08:45:00 +0000

Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal genetic disease—about a half million people in the U.S. alone suffer from the condition. There is currently no cure, but new research could open the door to new gene therapies for treating most cases of this kidney disease. For several decades, researchers have […]

The post New research may lead to gene therapies for kidney disease appeared first on Labiotech.eu.

Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch

Jim Cornall — Wed, 15 Mar 2023 17:00:25 +0000

Cambrian Bio, a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, has launched its new pipeline company, Amplifier Therapeutics. The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. Amplifier has also acquired Betagenon AB, a Swedish biopharmaceutical company, which has discovered novel AMPK activators. It will continue its work […]

The post Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch appeared first on Labiotech.eu.

Calliditas shares rise as phase 3 endpoints met in kidney disease trial

Jim Cornall — Tue, 14 Mar 2023 09:31:10 +0000

Swedish company Calliditas Therapeutics AB has announced positive topline results from the global, randomized, double-blind, placebo-controlled phase 3 clinical trial investigating the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). Calliditas share prices rose 30% in the aftermath of the announcement. IgAN, or Berger’s disease, is […]

The post Calliditas shares rise as phase 3 endpoints met in kidney disease trial appeared first on Labiotech.eu.

5 advancements in kidney disease research over the past year

Roohi Mariam Peter — Thu, 09 Mar 2023 12:39:11 +0000

Prevalent in millions of people across the globe, kidney diseases manifest through various symptoms like blood and excess protein in urine, fluid retention causing swollen ankles, poor appetite and even the inability of the body to filter waste, resulting in acute kidney failure. To boost the research and development of treatments for kidney diseases, Kidney […]

The post 5 advancements in kidney disease research over the past year appeared first on Labiotech.eu.

Orbsen Therapeutics happy with interim diabetic kidney disease study results

Jim Cornall — Thu, 26 Jan 2023 11:23:40 +0000

Orbsen Therapeutics Limited has announced what it says are encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for diabetic kidney disease. NEPHSTROM is a randomized, double-blind, placebo-controlled phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell immunotherapy, ORBCEL, in adult study […]

The post Orbsen Therapeutics happy with interim diabetic kidney disease study results appeared first on Labiotech.eu.

New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children

Jim Cornall — Mon, 14 Nov 2022 11:52:41 +0000

When we think about acute kidney injury (AKI) and multi-organ failure, we don’t often think about children. But approximately 4,000 pediatric patients in the U.S. each year have AKI requiring continual kidney replacement therapy (CKRT). These patient profiles are associated with long hospital stays, high morbidity and mortality (50%), and children who survive an AKI […]

The post New therapy transitions toxic immune cells from harmful to healing to fight effects of hyperinflammation in children appeared first on Labiotech.eu.

Early diagnosis tool for childhood kidney disease

Jim Cornall — Mon, 14 Nov 2022 10:29:02 +0000

Early diagnosis of chronic kidney disease (CKD) is key to managing progression of the disease. A new technique analyzing urine extracellular vesicles (uEVs) — cell-derived nanoscale spherical structures involved in multiple biological functions — in urine samples, identifies changes in the kidneys earlier than conventional methods and can also predict renal function decline. A team […]

The post Early diagnosis tool for childhood kidney disease appeared first on Labiotech.eu.

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

Liza Laws — Fri, 04 Nov 2022 19:09:01 +0000

A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […]

The post EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease appeared first on Labiotech.eu.

New drug application for chronic kidney disease sparks $35M milestone payment

Liza Laws — Mon, 31 Oct 2022 20:46:20 +0000

A submission has been made for a new drug application by Japanese Kyowa Kirin Co. Ltd. for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD). The company has submitted the application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor, which helps those with CKD on dialysis. Ardelyx, Inc. […]

The post New drug application for chronic kidney disease sparks $35M milestone payment appeared first on Labiotech.eu.

Rila Therapeutics exits stealth mode to address renal fibrosis

Jim Cornall — Fri, 28 Oct 2022 11:10:15 +0000

Rila Therapeutics, a biotherapeutics company focused on addressing the critical unmet medical needs to treat renal fibrosis, has emerged from stealth mode. Rila Therapeutics has identified a promising, first-in-class allosteric small molecule targeting HIPK2 to inhibit kidney fibrosis. The breakthrough discovery aiming to advance the treatment of renal disease was developed in collaboration with Mount […]

The post Rila Therapeutics exits stealth mode to address renal fibrosis appeared first on Labiotech.eu.

The hottest private biotech companies in Australia

Jonathan Smith — Tue, 18 Oct 2022 15:49:32 +0000

Australia has a strong base in biotechnology, with many incentives for R&D and commercialization. Here are the top five private Australian biotech companies that have recently showcased the country’s credentials in the sector. Australia is a highly developed nation in the Southern Hemisphere. Famous for its huge wool trade and iron ore wealth, the country […]

The post The hottest private biotech companies in Australia appeared first on Labiotech.eu.

Poxel granted orphan drug designation for kidney disease treatment

Jim Cornall — Mon, 03 Oct 2022 10:31:19 +0000

French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2 ready ADPKD asset, subject […]

The post Poxel granted orphan drug designation for kidney disease treatment appeared first on Labiotech.eu.

Everest Medicines gets go-ahead for renal disease drug study

Jim Cornall — Mon, 26 Sep 2022 06:20:37 +0000

Chinese biopharma company Everest Medicines says the China National Medical Products Administration (NMPA)’s Center for Drug Evaluation has approved the investigational new drug (IND) application for a phase 1b study of EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned phase 1b clinical study […]

The post Everest Medicines gets go-ahead for renal disease drug study appeared first on Labiotech.eu.

First treatment of rare kidney disease launched in Germany by STADA Arzneimittel

Liza Laws — Tue, 20 Sep 2022 14:44:37 +0000

The first and only approved treatment for primary immunoglobin A (IgA) nephropathy, a rare, progressive disease of the kidneys, has been launched in Germany. European commercial partner of Calliditas Therapeutics AB, STADA Arzneimittel AG, says the treatment will launch in additional European countries later. The disease, also known as Berger’s disease, occurs when immunoglobin builds […]

The post First treatment of rare kidney disease launched in Germany by STADA Arzneimittel appeared first on Labiotech.eu.

Research charity calls on scientists, engineers, and technology experts to transform dialysis treatment

External Contributor — Tue, 13 Sep 2022 08:59:01 +0000

Following its successful MedTech competition earlier this year, the UK’s largest kidney research charity, Kidney Research UK, has launched a new competition aimed at innovations in dialysis that will have a significant impact on patients’ lives. In collaboration with IN-PART’s Discover platform, this year’s competition will encourage scientists, academics, engineers and technology experts to propose […]

The post Research charity calls on scientists, engineers, and technology experts to transform dialysis treatment appeared first on Labiotech.eu.

Drug to treat rare kidney disease to be reviewed by EMA

Liza Laws — Mon, 22 Aug 2022 16:33:07 +0000

The European Medicines Agency (EMA) has agreed to review a conditional marketing authorization (CMA) application for a drug to treat a rare kidney disorder. The news was announced today (August 21) by CSL Vifor and Travere Therapeutics Inc, and, if approved, the companies say sparsentan will address a significant unmet need in treating IgA nephropathy […]

The post Drug to treat rare kidney disease to be reviewed by EMA appeared first on Labiotech.eu.

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Jim Cornall — Thu, 11 Aug 2022 12:02:04 +0000

Synlogic, Inc. has announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks. The new candidate, SYNB2081, is a synthetic biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential […]

The post Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout appeared first on Labiotech.eu.